Regeneron (REGN) Reports Positive 2-Yr Results from Phase 3 PANORAMA Trial Evaluating EYLEA (aflibercept) Injection 2mg

Go back to Regeneron (REGN) Reports Positive 2-Yr Results from Phase 3 PANORAMA Trial Evaluating EYLEA (aflibercept) Injection 2mg
Regeneron (NASDAQ: REGN) Delayed: 784.85 -4.6 (0.58%)
Previous Close $789.45    52 Week High $592.36 
Open $787.34    52 Week Low $325.35 
Day High $794.73    P/E 206.00 
Day Low $779.65    EPS $3.81 
Volume 2,473,425